Clinical Trial Update: Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab in HER2-positive metastatic breast cancer has been terminated; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Capecitabine (capecitabine)
• Lapatinib Ditosylate (lapatinib ditosylate)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of Southern California | Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-10-05